Safety of low-dose spironolactone administration in chronic haemodialysis patients.


BACKGROUND Prevention of cardiovascular diseases is essential in chronic haemodialysis patients. Recently, low-dose spironolactone has been shown to decrease cardiovascular mortality in patients with severe heart failure. However, since haemodialysis patients are prone to hyperkalaemia, a known side effect of spironolactone, this treatment is not used in… (More)


  • Presentations referencing similar topics